Clinical aspects and distribution of immunologically active cells in the nasal mucosa of patients with nasal polyps after endoscopic sinus surgery and treatment with topical corticosteroids.
Clinical parameters of 72 patients who were operated upon for nasal polyps were evaluated as well as biopsy specimens of the mucosa of the middle and inferior turbinates of 41 of these patients. Biopsies were taken at the time of endoscopic sinus surgery (ESS), after 6 months and after 1 year in 23 patients. During the follow-up period the patients were treated with topical corticosteroids (budesonide). At the time of ESS significantly more CD8+ (suppressor/cytotoxic) cells than CD4+ (helper/inducer) cells were found in the middle and inferior turbinates. At 6 months significantly more CD4+ cells were found than at the time of ESS, whereas at 1 year the number of CD4+ cells had decreased and was lower than at 6 months. These data support the theory that the occurrence of nasal polyps is associated with T-cell-dependent disturbances. Clinical evaluation revealed that most of the patients with chronic airway obstruction had better pulmonary functions postoperatively or required less medication for lung disease. These findings show that ESS combined with topical corticosteroids has a positive effect on upper and lower respiratory tract pathology.
Stoop
A E
AE
Department of Otorhinolaryngology/Head and Neck Surgery, Free University Hospital, Amsterdam, The Netherlands.
van der Heijden
H A
HA
Biewenga
J
J
van der Baan
S
S
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000032:analysis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D019819:Budesonide; D018801:CD2 Antigens; D016516:CD4-CD8 Ratio; D015815:Cell Adhesion Molecules; D003131:Combined Modality Therapy; D004724:Endoscopy; D005938:Glucocorticoids; D006801:Humans; D037102:Lectins; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology*; D008875:Middle Aged; D009297:Nasal Mucosa / Q000276:immunology* / Q000473:pathology; D009298:Nasal Polyps / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000601:surgery*; D011282:Pregnenediones / Q000008:administration & dosage*; D011971:Receptors, Immunologic / Q000032:analysis; D051918:Sialic Acid Binding Ig-like Lectin 2
D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; C497867:CD22 protein, human; D015815:Cell Adhesion Molecules; D005938:Glucocorticoids; D037102:Lectins; D011282:Pregnenediones; D011971:Receptors, Immunologic; D051918:Sialic Acid Binding Ig-like Lectin 2; D019819:Budesonide